Kat Lynch - Blog

After Q4 Earnings Calls: Comparing Industry Outlook and Physician Perspectives

During Q4 earnings calls, biopharmaceutical companies reflected on the cumulative impact of the COVID-19 pandemic. An assessment of US-based physician sentiment (n=62) provides a useful ‘on-the-ground’ perspective to further examine these issues.

Covid-19

Q3 Earnings Calls Presented a Case for Cautious Optimism

Having weathered many challenges in Q2 2020, biopharmaceutical firms, by and large, presented a case for optimism during Q3 2020 earnings calls. However, alongside this optimistic outlook were a number of voices expressing

Covid-19

Q2 Earnings Calls Provide Insight on the Future of In-Person Promotional Activity

A return to pre-pandemic levels of in-person promotional activity looks increasingly uncertain in H2 2020. Given this uncertainty, pharmaceutical manufacturers, from diversified, multinational firms to more focused, growth-stage companies are navigating the complexities

Covid-19

Q1 Earnings Calls Provide Insight into the Future of In-Person Promotional Activity

Pharmaceutical manufacturers, from diversified, multinational firms to focused, growth-stage companies are adapting to the reality of COVID-19. Recent Q1 investor calls provide insight into both the impact of the pandemic thus far on

Research

ZoomRx, MGH, and the Sumaira Foundation Collaborate on Newly Published NMO Research

When approached by the Global Neurology Research Group at Mass General Hospital (along with the Sumaira Foundation) with the opportunity to collaborate on a global study of neuromyelitis optica (NMO), we were eager